The Medical Alert Monitoring Association (MAMA) recently wrapped up its annual conference in Washington D.C. on September 24 and 25. The event gathered industry leaders, healthcare professionals, and advocates dedicated to supporting aging adults. Over two days, discussions centered on…
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company focused on developing first-in-class logic-gated cell therapies to selectively target tumor cells while protecting healthy cells, has announced that six of its abstracts have been accepted for presentation at the…
Kerecis, a leader in the use of fish skin and fatty acids for tissue regeneration, has announced the publication of significant study results in the New England Journal of Medicine Evidence. This research, involving 255 patients across 15 care centers…
Aulos Bioscience, an immuno-oncology company focused on advancing cancer care through innovative IL-2 therapeutics, has announced the presentation of encouraging safety and efficacy data from the Phase 2 dose expansion cohorts of its Phase 1/2 clinical trial for AU-007. This…
Peak Mobile Vascular Access is expanding its services to the Midwest, aiming to offer its exceptional vascular access solutions—such as PICC lines, Midlines, and Peripheral IVs—to a wider audience. This strategic move ensures high-quality care and enhanced convenience for both…
Exact Sciences Corp. (NASDAQ: EXAS), a prominent provider of cancer screening and diagnostic solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved its next-generation multitarget stool DNA test, Cologuard Plus™. This test is now authorized for…
Summit Therapeutics Inc. (NASDAQ: SMMT) has announced the completion of patient enrollment in its HARMONi clinical trial. This multi-regional Phase III study evaluates ivonescimab combined with platinum-doublet chemotherapy versus placebo with platinum-doublet chemotherapy for patients with epidermal growth factor receptor…
Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) with tumors ≥4 cm or node-positive, and no known EGFR mutations…
HealthAxis, a leader in healthcare administration technology, has partnered with COPE Health Solutions (CHS), a specialist in value-based care and population health management. This strategic collaboration aims to provide comprehensive, end-to-end solutions for health plans and providers engaged in value-based…
DeepCure, a therapeutics company leveraging AI to discover innovative drugs for inflammation and immune diseases, today announced that it will present data demonstrating that its selective BRD4 (BD2) inhibitor, DC-9476, is more effective than anti-TNF-α treatment in a collagen antibody-induced…
